Controlled release formulations for the delivery of HIF-1 inhibitors

US8962577B2 · kind B2 · utility

Assignee

• THE JOHNS HOPKINS UNIVERSITY · US

Inventors

• Justin Hanes · Baltimore, US
• Peter A. Campochiaro · Baltimore, US
• Jie Fu · Beijing, CN

Key dates

• Filing date: Mar 12, 2013
• Grant date: Feb 24, 2015
• Expiry date: Mar 12, 2033

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P27/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Controlled release dosage formulations for the delivery of one or more HIF-1 inhibitors are provided. The controlled release formulations contain one or more HIF-1 inhibitors conjugated to or dispersed in a polymeric vehicle. The one or more HIF-1 inhibitors can be dispersed or encapsulated in a polymeric matrix. In some embodiments, the one or more HIF-1 inhibitors are covalently bound to a polymer, forming a polymer-drug conjugate. Polymeric vehicles can be formed into implants, microparticles, nanoparticles, or combinations thereof. Controlled release HIF-1 formulations provide prolonged therapeutic benefit while lowering side effects by releasing low levels of one or more HIF-1 inhibitors and/or HIF-1 inhibitor conjugates over a prolonged period of time. Controlled release dosage formulations can be used to treat or prevent a disease or disorder in a patient associated with vascularization, including cancer, obesity, and ocular diseases such as wet AMD.